Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Why Global Web3 Projects Can't Afford to Skip South Korea: TokenPost Unveils Data-Driven Entry Solutions 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
U.S. Demand for Alternative Satellite Providers Remains Strong Amid SpaceX Regulatory Push 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Nomura Shares Drop After Profit Miss Despite Strong Revenue Growth 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
NEW YORK, April 06, 2017 -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of INSYS Therapeutics, Inc. (NASDAQ:INSY) who purchased shares between February 23, 2016 and March 15, 2017. The action, which was filed in the United States District Court for the Southern District of New York, alleges that the Company violated federal securities laws.
In particular, the complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) accordingly, the Company lacked effective internal controls over financial reporting; and (4) as a result, INSYS' public statements were materially false and misleading at all relevant times.
Shareholders have until May 16, 2017 to petition the court for lead plaintiff status. Your ability to share in any recovery does not require that you serve as lead plaintiff. You may choose to be an absent class member.
If you suffered a loss during the class period and wish to obtain additional information, please contact Joseph Klein, Esq. by telephone at 212-616-4899 or visit http://www.kleinstocklaw.com/pslra-sa/insys-therapeutics-inc.
Joseph Klein, Esq. is an experienced attorney and has also practiced as a Certified Public Accountant. Mr. Klein represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Joseph Klein, Esq. Empire State Building 350 Fifth Avenue 59th floor New York, NY 10118 Telephone: (212) 616-4899 Fax: (347) 558-9665 www.kleinstocklaw.com
